Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part D Starts Slow

This article was originally published in RPM Report

Executive Summary

The new Medicare drug benefit generated plenty of controversy in its first weeks, but the start-up glitches have very little to do with the long term outlook for the program. One key factor matters for 2006: enrollment. And with just 3.6 million voluntary sign-ups so far, Part D is not off to a fast start.

You may also be interested in...



Unapproved Drugs Become Unpaid Drugs, Effective January 1

Pharmacies and wholesalers are expressing their concern about the potential for an upcoming policy change in Part D to disrupt dispensing. Beginning Jan. 1, any medication that does not have an NDC registered with FDA will no longer be covered by the drug benefit.

MedPAC On Steroids: The Implications of a New Medicare Advisory Council

The creation of an independent health council to weigh in on Medicare reimbursement rates may be part of a final health reform bill. The idea has a number of implications for biopharma-good and bad.

Tilting the Contracting Scales: Part D Plans Have Advantages Over Manufacturers in 2008

Contracting between pharma companies and Part D plan sponsors that took place last year for 2007 pricing and formulary placement was a relatively straightforward process. This year will be more interesting.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS080019

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel